Abstract: The present invention provides a phosphonic acid compound and a prodrug thereof, and preparation methods for and uses of the phosphonic acid compound and the prodrug thereof. Specifically, the present invention provides a compound of formula (I) or formula (I-A), wherein the compound of formula (I-A) is a prodrug form of the compound of formula (I). Upon experimental verification, the phosphonic acid compound of the present invention has good ENPP1 kinase inhibition activity, and can be used as a therapeutic agent for ENPP1-related diseases, and the phosphonic acid compound has good metabolic stability in-vivo. In addition, the phosphonate or amide prodrug compound provided by the present invention has relatively high oral bioavailability, and can overcome the defect that a phosphonic acid original drug compound cannot be taken orally.

Abstract: The present disclosure involves a compound of formula (I) having ENPP1 inhibitory activity, a pharmaceutical composition thereof, and use thereof. The present disclosure particularly involves a compound of formula (I), as well as a pharmaceutical composition containing the compound and a method for preventing or treating diseases using the compound, particularly for diseases or disorders mediated by ENPP1 abnormal activity.

Abstract: Provided are a compound as a PD-L1 inhibitor, a preparation method therefor, and use thereof. Further provided is use of the compound or a pharmaceutical composition thereof in the preparation of a medicine, wherein the medicine is used for preventing and treating a PD-L1-related disease.